The Value of Interleukin-17A as a Prognostic Indicator in COVID-19 Patients

Background: SARS-CoV-2 infections (COVID-19) first occurred in Wuhan, China, December 2019 and spread worldwide, causing significant mortality morbidity. IL-17A may mediate numerous immunopathological effects secondary to cytokine release syndrome during infection. However, there has not been enough research on its effect prognosis. Objectives: This study evaluated the predictive power of serum interleukin (IL)-17A level as a prognostic marker COVID-19. Methods: The included 152 patients diagnosed with COVID-19 by real-time polymerase chain reaction analysis nasopharyngeal swab samples infectious diseases department intensive care unit our hospital between October 1 31, 2020. control group consisted 40 asymptomatic healthcare workers who had negative RT-PCR results routine screening hospital. Samples were collected anticoagulant-free tubes left at room temperature for 30 minutes. Afterward, it was centrifuged 1000 × g 15 minutes 4°C per instructions provided enzyme-linked immunoassay (ELISA) kit. Serum levels measured using Human Interleukin 17A ELISA Kit. Results: significantly higher than controls (P < 0.001). increased association disease severity moderate, severe, critical disease, less pronounced difference severe (moderate vs. P 0.001; critical, = 0.048). admission day 7 non-surviving At cut-off value 210.25 ng/L, 0.792 Compared baseline, values seven non-survivors 0.004) decreased survivors 0.014). An increase 26.17 ng/L or more 0.634 0.005). Conclusions: this suggest that IL-17A, an important part immune system previously shown be useful treatment follow-up COVID-19, also help predict patients.